Amgen "Neck and Neck" With Competitors in Race for New Anti-Cholesterol Drugs Approval
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
In one of the most closely-watched medical races of all time, Amgen and rival pharmaceutical companies are chasing approval for new anti-cholesterol drugs that have the potential to be blockbusters. Cardiologists see them as the single most promising class of drugs currently in development, said Dr. Steven Nissen, the department chair of cardiovascular medicine at the Cleveland Clinic. For its new cholesterol-fighting drug, AMG 145, Thousand Oaks-based Amgen expects to have data from its pre-marketing clinical trial period available in early 2014.
Help employers find you! Check out all the jobs and post your resume.
In one of the most closely-watched medical races of all time, Amgen and rival pharmaceutical companies are chasing approval for new anti-cholesterol drugs that have the potential to be blockbusters. Cardiologists see them as the single most promising class of drugs currently in development, said Dr. Steven Nissen, the department chair of cardiovascular medicine at the Cleveland Clinic. For its new cholesterol-fighting drug, AMG 145, Thousand Oaks-based Amgen expects to have data from its pre-marketing clinical trial period available in early 2014.
Help employers find you! Check out all the jobs and post your resume.